ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CGTX Cognition Therapeutics Inc

1.92
-0.07 (-3.52%)
08 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Cognition Therapeutics Inc CGTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.07 -3.52% 1.92 08:44:37
Open Price Low Price High Price Close Price Previous Close
1.98 1.9001 2.00 1.92 1.99
more quote information »

Recent News

Date Time Source Heading
07/5/202421:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202421:39EDGAR2Form 8-K - Current report
12/3/202407:11EDGAR2Form 8-K - Current report
12/3/202407:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/2/202408:44EDGAR2Form 8-K - Current report
21/2/202408:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202408:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/2/202411:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202407:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/1/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
09/1/202408:11EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/1/202408:21EDGAR2Form 8-K - Current report
04/1/202423:30GLOBECognition Therapeutics CEO Issues Letter to Shareholders
30/12/202308:02EDGAR2Form S-3 - Registration statement under Securities Act of..
16/11/202323:30GLOBECognition Therapeutics Releases New Episode of..
15/11/202323:30GLOBECognition Therapeutics Presents Preclinical Data Identifying..
14/11/202309:25EDGAR2Form SC 13D/A - General statement of acquisition of..
14/11/202301:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202301:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202323:30GLOBECognition Therapeutics Completes Enrollment in Phase 2 SHINE..
02/11/202322:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202322:41EDGAR2Form 8-K - Current report
02/11/202322:30GLOBECognition Therapeutics Reports Third Quarter 2023 Financial..
27/10/202322:30GLOBECognition Therapeutics and Collaborators at Yale and ACTC..
25/10/202307:30GLOBECognition Therapeutics Presents Complete EEG Findings from..
16/10/202322:30GLOBECognition Therapeutics Presents New Data at CTAD Conference..
12/9/202321:00EDGAR2Form 8-K - Current report
07/9/202321:45GLOBECognition Therapeutics Announces New Conversations Episode..
30/8/202322:00GLOBECognition Therapeutics Announces Participation in Upcoming..
24/8/202321:00EDGAR2Form 8-K - Current report
08/8/202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202321:05EDGAR2Form 8-K - Current report
08/8/202321:00GLOBECognition Therapeutics Reports Second Quarter 2023 Financial..
02/8/202321:30GLOBECognition Therapeutics to Report Second Quarter 2023 Results..
11/7/202321:30GLOBECognition Therapeutics Announces Dosing of First Patient in..
05/7/202321:30GLOBECognition Therapeutics and the Alzheimer's Clinical Trials..
28/6/202321:00GLOBECognition Therapeutics Announces Positive Topline Results..
28/6/202309:17GLOBECognition Therapeutics to Host Call and Webcast to Discuss..
20/6/202321:30GLOBECognition Therapeutics Invited to Participate on Panel..
02/6/202321:30GLOBECognition Therapeutics Continues Investor Engagement in June..
23/5/202321:30GLOBECognition Therapeutics Latest Episode of “Conversations”..
18/5/202321:30GLOBECognition Therapeutics Publishes Clinical Evidence that..

Your Recent History

Delayed Upgrade Clock